Proteome profiling of vitreoretinal diseases by cluster analysis

Proteomics - Clinical Applications

Volumn 2, Issue 9, 2008, Pages 1265-1280

  Shitama, Tomomi ^a,b   Hayashi, Hideyuki ^b   Noge, Sumiyo ^b   Uchio, Eiichi ^b   Oshima, Kenji ^b   Haniu, Hisao ^a   Takemori, Nobuaki ^a   Komori, Naoka ^a   Matsumoto, Hiroyuki ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cluster analysis; Marker proteins; Quantitative proteomics; Two dimensional gel; Vitreoretinal diseases

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A4; TRANSFERRIN;

ADULT; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RETINA DETACHMENT; TWO DIMENSIONAL GEL ELECTROPHORESIS; VITREORETINOPATHY; VITREOUS BODY;

EID: 53549115616     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800017     Document Type: Article

References (77)

1. Aiello, L. P., Gardner, T. W., King, G. L., Blankenship, G. et al., Diabetic retinopathy. Diabetes Care 1998, 21, 143-156.
2. Caird, F. I., The epidemiology of diabetic microangiopathy. Acta Diabetol. Lat. 1971, 8 Suppl 1, 240-248.
3. Grierson, I., Mazure, A., Hogg, P., Hiscott, P. et al., Non-vascular vitreoretinopathy: the cells and the cellular basis of contraction. Eye 1996, 10, 671-684.
4. Schwartz, S. D., Kreiger, A. E., Proliferative vitreoretinopathy: a natural history of the fellow eye. Ophthalmology 1998, 105, 785-788.
5. Arden, G. B., Hamilton, A. M., Wilson-Holt, J., Ryan, S. et al., Pattern electroretinograms become abnormal when background diabetic retinopathy deteriorates to a preproliferative stage: possible use as a screening test. Br. J. Ophthalmol. 1986, 70, 330-335.
6. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983, 90, 121-125.
7. Machemer, R., Pathogenesis and classification of massive periretinal proliferation. Br. J. Ophthalmol. 1978, 62, 737-747.
8. Machemer, R., Laqua, H., A logical approach to the treatment of massive periretinal proliferation. Ophthalmology 1978, 85, 584-593.
9. Ryan, S. J., The pathophysiology of proliferative vitreoretinopathy in its management. Am. J. Ophthalmol. 1985, 100, 188-193.
10. Weller, M., Wiedemann, P., Heimann, K., Proliferative vitreoretinopathy-is it anything more than wound healing at the wrong place? Int. Ophthalmol. 1990, 14, 105-117.
11. Harry, J. L., Wilkins, M. R., Herbert, B. R., Packer, N. H. et al., Proteomics: capacity versus utility. Electrophoresis 2000, 21, 1071-1081.
12. Matsumoto, H., Kurono, S., Matsumoto, M., Komori, N., in: Meyers, R. A., (Ed.), Encyclopedia of Molecular and Cell Biology and Molecular Medicine, Wiley-VCH Verlag, Weinheim; 2005, 2nd edn., pp. 557-585.
13. Haniu, H., Komori, N., Takemori, N., Singh, A. et al., Proteomic trajectory mapping of biological transformation: Application to developmental mouse retina. Proteomics 2006, 6, 3251-3261.
14. Komori, N., Takemori, N., Kim, H. K., Singh, A. et al., Proteomics study of neuropathic and nonneuropathic dorsal root ganglia: altered protein regulation following segmental spinal nerve ligation injury. Physiol. Genomics 2007, 29, 215-230.
15. Garcia-Ramirez, M., Canals, F., Hernandez, C., Colome, N. et al., Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007, 50, 1294-1303.
16. Deeg, C. A., Altmann, F., Hauck, S. M., Schoeffmann, S. et al., Down-regulation of pigment epithelium-derived factor in uveitic lesion associates with focal vascular endothelial growth factor expression and breakdown of the blood - retinal barrier. Proteomics 2007, 7, 1540-1548.
17. de Boer, J. H., van Haren, M. A., de Vries-Knoppert, W. A., Baarsma, G. S. et al., Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr. Eye Res. 1992, 11 Suppl, 181-186.
18. Funatsu, H., Yamashita, H., Ikeda, T., Mimura, T. et al., Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003, 110, 1690-1696.
19. Hattenbach, L. O., Allers, A., Gumbel, H. O., Scharrer, I., Koch, F. H., Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy. Retina 1999, 19, 383-389.
20. Lam, R. F., Yuen, H. K., Lam, D. S., Vitreous VEGF secretion. Ophthalmology 2005, 112, 1483; author reply 1483.
21. Nakanishi, T., Koyama, R., Ikeda, T., Shimizu, A., Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole. J Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 776, 89-100.
22. Neal, R. E., Bettelheim, F. A., Lin, C., Winn, K. C. et al., Alterations in human vitreous humour following cataract extraction. Exp. Eye Res. 2005, 80, 337-347.
23. Ouchi, M., West, K., Crabb, J. W., Kinoshita, S., Kamei, M., Proteomic analysis of vitreous from diabetic macular edema. Exp. Eye Res. 2005, 81, 176-182.
24. Wu, C. W., Sauter, J. L., Johnson, P. K., Chen, C. D., Olsen, T. W., Identification and localization of major soluble vitreous proteins in human ocular tissue. Am. J. Ophthalmol. 2004, 137, 655-661.
25. Yamane, K., Minamoto, A., Yamashita, H., Takamura, H. et al., Proteome analysis of human vitreous proteins. Mol. Cell. Proteomics 2003, 2, 1177-1187.
26. Matsumoto, H., Komori, N., Ocular proteomics: cataloging photoreceptor proteins by two-dimensional gel electrophoresis and mass spectrometry. Methods Enzymol. 2000, 316, 492-511.
27. Carr, S., Aebersold, R., Baldwin, M., Burlingame, A. et al., The need for guidelines in publication of peptide and protein identification data: Working Group on Publication Guidelines for Peptide and Protein Identification Data. Mol. Cell. Proteomics 2004, 3, 531-533.
28. Bradshaw, R. A., Revised draft guidelines for proteomic data publication. Mol. Cell. Proteomics 2005, 4, 1223-1225.
29. Tamayo, P., Slonim, D., Mesirov, J., Zhu, Q. et al., Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc. Natl. Acad. Sci. USA 1999, 96, 2907-2912.
30. Blomback, B., Blomback, M., The molecular structure of fibrinogen. Ann. NY Acad. Sci. 1972, 202, 77-97.
31. Hessel, B., Makino, M., Iwanaga, S., Blomback, B., Primary structure of human fibrinogen and fibrin. Structural studies on NH2-terminal part of B beta chain. Eur. J. Biochem. 1979, 98, 521-534.
32. Clausen, R., Weller, M., Wiedemann, P., Heimann, K. et al., An immunochemical quantitative analysis of the protein pattern in physiologic and pathologic vitreous. Graefes Arch. Clin. Exp. Ophthalmol. 1991, 229, 186-190.
33. Barzilay, J. I., Abraham, L., Heckbert, S. R., Cushman, M. et al., The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50, 2384-2389.
34. Freeman, D. J., Norrie, J., Caslake, M. J., Gaw, A. et al., C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002, 51, 1596-1600.
35. Han, T. S., Sattar, N., Williams, K., Gonzalez-Villalpando, C. et al., Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002, 25, 2016-2021.
36. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E., Ridker, P. M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286, 327-334.
37. Gerhardinger, C., Costa, M. B., Coulombe, M. C., Toth, I. et al., Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest. Ophthalmol. Vis. Sci. 2005, 46, 349-357.
38. El-Ghrably, I. A., Dua, H. S., Orr, G. M., Fischer, D., Tighe, P. J., Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br. J. Ophthalmol. 2001, 85, 461-470.
39. Funatsu, H., Yamashita, H., Sakata, K., Noma, H. et al., Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2006, 112, 806-816.
40. Krady, J. K., Basu, A., Allen, C. M., Xu, Y. et al., Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005, 54, 1559-1565.
41. Limb, G. A., Alam, A., Earley, O., Green, W. et al., Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr. Eye Res. 1994, 13, 791-798.
42. Bonini-Filho, M. A., Jorge, R., Barbosa, J. C., Calucci, D. et al., Intravitreal injection versus sub-tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest. Ophthalmol. Vis. Sci. 2005, 46, 3845-3849.
43. Larsson, J., Zhu, M., Sutter, F., Gillies, M. C., Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am. J. Ophthalmol. 2005, 139, 802-806.
44. Letcher, R. L., Chien, S., Pickering, T. G., Laragh, J. H., Elevated blood viscosity in patients with borderline essential hypertension. Hypertension 1983, 5, 757-762.
45. Lominadze, D., Joshua, I. G., Schuschke, D. A., Increased erythrocyte aggregation in spontaneously hypertensive rats. Am. J. Hypertens. 1998, 11, 784-789.
46. Kannel, W. B., D'Agostino, R. B., Belanger, A. J., Sibershatz, H., Tofler, G. T., Long-term influence of fibrinogen on initial and recurrent cardiovascular events in men and women. Am. J. Cardiol. 1996, 78, 90-92.
47. Stec, J. J., Silbershatz, H., Tofler, G. H., Matheney, T. H. et al., Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000, 102, 1634-1638.
48. Woodward, M., Lowe, G. D., Rumley, A., Tunstall-Pedoe, H., Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur. Heart J. 1998, 19, 55-62.
49. Borsey, D. Q., Prowse, C. V., Gray, R. S., Dawes, J. et al., Platelet and coagulation factors in proliferative diabetic retinopathy. J. Clin. Pathol. 1984, 37, 659-664.
50. Kostraba, J. N., Klein, R., Dorman, J. S., Becker, D. J. et al., The epidemiology of diabetes complications study. IV. Correlates of diabetic background and proliferative retinopathy. Am. J. Epidemiol. 1991, 133, 381-391.
51. Shiose, S., Hata, Y., Noda, Y., Sassa, Y. et al., Fibrinogen stimulates in vitro angiogenesis by choroidal endothelial cells via autocrine VEGF. Graefes Arch. Clin. Ex. Ophthalmol. 2004, 242, 777-783.
52. Mosesson, M. W., Siebenlist, K. R., Meh, D. A., The structure and biological features of fibrinogen and fibrin. Ann. NY Acad. Sci. 2001, 936, 11-30.
53. Cao, W., Tombran-Tink, J., Chen, W., Mrazek, D. et al., Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death. J. Neurosci. Res. 1999, 57, 789-800.
54. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E. et al., Pigment epithelium-derived factor: a patent inhibitor of angiogenesis. Science 1999, 285, 245-248.
55. Duh, E. J., Yang, H. S., Haller, J. A., De Juan, E. et al., Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am. J. Ophthalmol. 2004, 137, 668-674.
56. Ogata, N., Nishikawa, M., Nishimura, T., Mitsuma, Y., Matsumura, M., Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Am. J. Ophthalmol. 2002, 133, 851-852.
57. Wang, X. F., Cui, J. Z., Nie, W., Prasad, S. S., Matsubara, J. A., Differential gene expression of early and late passage retinal pigment epithelial cells. Exp. Eye Res. 2004, 79, 209-221.
58. Gwon, J. S., Kim, I. B., Lee, M. Y., Oh, S. J., Chun, M. H., Expression of clusterin in Muller cells of the rat retina after pressure-induced ischemia. Glia 2004, 47, 35-45.
59. Hayasaka, S., Hara, S., Mizuno, K., Partial purification and properties of cathepsin D in the retinal pigment epithelium. Invest. Ophthalmol. 1975, 14, 617-620.
60. Yamada, T., Hara, S., Tamai, M., Immunohistochemical localization of cathepsin D in ocular tissues. Invest. Ophthalmol. Vis. Sci. 1990, 31, 1217-1223.
61. Boulton, M., Moriarty, P., Jarvis-Evans, J., Marcyniuk, B., Regional variation and age-related changes of lysosomal enzymes in the human retinal pigment epithelium. Br. J. Ophthalmol. 1994, 78, 125-129.
62. Hayasaka, S., Hara, S., Mizuno, K., Lysosomal enzymes in subretinal fluid. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 1976, 200, 13-20.
63. Cavallaro, T., Martone, R. L., Dwork, A. J., Schon, E. A., Herbert, J., The retinal pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Invest. Ophthalmol. Vis. Sci. 1990, 31, 497-501.
64. Martone, R. L., Schon, E. A., Goodman, D. S., Soprano, D. R., Herbert, J., Retinol-binding protein is synthesized in the mammalian eye. Biochem. Biophys. Res. Commun. 1988, 157, 1078-1084.
65. Jordan-Starck, T. C., Lund, S. D., Witte, D. P., Aronow, B. J. et al., Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J. Lipid Res. 1994, 35, 194-210.
66. Jenne, D. E., Tschopp, J., Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 1992, 17, 154-159.
67. May, P. C., Robison, P., Fuson, K., Smalstig, B. et al., Sulfated glycoprotein-2 expression increases in rodent brain after transient global ischemia. Brain Res. Mol. Brain Res. 1992, 15, 33-39.
68. Klimaschewski, L., Obermuller, N., Witzgall, R., Regulation of clusterin expression following spinal cord injury. Cell Tissue Res. 2001, 306, 209-216.
69. Agarwal, N., Jomary, C., Jones, S. E., O'Rourke, K. et al., Immunocytochemical colocalization of clusterin in apoptotic photoreceptor cells in retinal degeneration slow rds mutant mouse retinas. Biochem. Biophys. Res. Commun. 1996, 225, 84-91.
70. Rakoczy, P. E., Lai, C. M., Baines, M., Di Grandi, S. et al., Modulation of cathepsin D activity in retinal pigment epithelial cells. Biochem. J. 1997, 324, 935-940.
71. Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I. et al., Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 1997, 336, 466-473.
72. Sanner, M. F., Olson, A. J., Spehner, J. C., Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 1996, 38, 305-320.
73. Hamilton, J. A., Benson, M. D., Transthyretin: a review from a structural perspective. Cell. Mol. Life Sci. 2001, 58, 1491-1521.
74. Felding, P., Fox, G., Cellular origin of prealbumin in the rat. Biochim. Biophys. Acta 1982, 716, 446-449.
75. Dickson, P. W., Howlett, G. J., Schreiber, G., Rat transthyretin (prealbumin). Molecular cloning, nucleotide sequence, and gene expression in liver and brain. J. Biol. Chem. 1985, 260, 8214-8219.
76. Soprano, D. R., Herbert, J., Soprano, K. J., Schon, E. A., Goodman, D. S., Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J. Biol. Chem. 1985, 260, 11793-11798.
77. Gao, B. B., Clermont, A., Rook, S., Fonda, S. J. et al., Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 2007, 13, 181-188.